Dhaval Desai
Interventional Cardiology · Corona, CANPI 1164798153
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.8%), grants and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Amryt Pharma Holdings Ltd at 56.8% of the total. Reporting peaked in 2023 at $67,315 and has fallen 97.7% since, to $1,527 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $631.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amryt Pharma Holdings Ltd$67K
- Boston Scientific$26K
- Medtronic$19K
- Edwards Lifesciences$3K
- Abbott$436
- AstraZeneca$318
- plus $2K from 24 others
What the payments were for
- Consulting fees$67,08657%
- Grants$43,00036%
- Travel & lodging$6121%
- Food & beverage$7,2516%
- Education$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amryt Pharma Holdings Ltd | 5 | $67,086 |
| Boston Scientific | 21 | $25,890 |
| Medtronic(2 entities) | 23 | $19,307 |
| Edwards Lifesciences | 36 | $2,836 |
| Abbott | 8 | $436 |
| AstraZeneca(2 entities) | 14 | $318 |
| Chiesi USA, Inc. | 8 | $221 |
| W. L. Gore & Associates, Inc. | 2 | $215 |
| Shockwave Medical, Inc | 7 | $194 |
| Novartis | 12 | $192 |
| Philips North America LLC | 4 | $182 |
| Cardiovascular Systems Inc. | 3 | $165 |
| Abiomed | 1 | $127 |
| Biotronik Inc. | 4 | $124 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $92 |
| Johnson & Johnson | 6 | $89 |
| Acist Medical Systems, Inc. | 3 | $88 |
| Terumo Medical Corporation | 3 | $78 |
| Baylis Medical Company Inc | 1 | $60 |
| Boehringer Ingelheim | 2 | $56 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Bardy Diagnostics, Inc. | 4 | $54 |
| Merck | 3 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $46 |
| Cardinal Health 200 LLC | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Ablacon, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Amgen | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYALEPT$67,086
- GENERAL - STRUCTURAL HEART$25,000
- CoreValve Evolut$18,693
- SAPIEN 3 Ultra RESILIA$898
- Edwards SAPIEN 3 Transcatheter Heart Valve$872
- Optis Coronary Imaging System$307
- SYNERGY$256
- COREVALVE EVOLUT R$143
- Vascular Graft$133
- Coronary Orbital Atherectomy System$130
- Impella$127
- KENGREAL$125
- LOTUS EDGE$117
- IGT D Coronary$116
- BRILINTA$112
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$111
How this compares
$118,097 in reported general payments places this provider in the 90th percentile of 585 interventional cardiology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 27 | $507 |
| Furosemide | 15 | $153 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Corona
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.